The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer

Targeting the sigma-2 receptor with a cytotoxic payload was effective in all the three cell lines evaluated and provides the proof of concept for future development of a therapeutic platform for the treatment of TNBC.